| Numéro de catalogue | HF941056 |
|---|
| Reactivité des espèces | Human |
|---|
| Applications | ELISA, Functional assay, Research in vivo |
|---|
| Clonalité | Monoclonal |
|---|
| Isotype | Tumor Necrosis Factor Receptor superfamily protein TNFRSF13b fusion with IgG1 Fc Fragment. |
|---|
| Activité biologique |
Povetacicept (0.137-33.3 nM; 240-1800 s) binds to recombinant human APRIL with a K d value of 1.00 pM, and also binds to recombinant human BAFF with a K d value of 59.3 pM, exhibiting high-affinity dual binding activity toward these two cytokines [2]. Povetacicept (2.5 pM-200 nM; 5 h) potently inhibits the signaling pathways of APRIL, BAFF, BAFF 60-mer and BAFF/APRIL heterotrimer in TACI/Jurkat/NF-κB reporter cells [2]. Povetacicept (7 d) potently inhibits the proliferation of primary human B cells, the differentiation of class-switched memory B cells into plasma cells, and the secretion of immunoglobulins [2]. Parmacokinetics Species Dose Route C max AUC Cynomolgus Monkey [2] 9 mg/kg i.v. 27 ug/mL 1167 ug·h/mL Povetacicept (10 mg/kg; i.p.; twice weekly; 3.5 weeks) significantly reduces bone marrow antibody-secreting cell counts, suppresses autoantibody production, and increases hematocrit in an HOD + OTII + mouse model of AIHA [1]. Povetacicept (15 mg/kg; i.p.; 2 doses (days 4 and 11)) potently reduces splenic immune cell subsets and inhibits T cell-dependent antibody formation more effectively than WT TACI-Fc comparators in KLH-immunized mice [2]. Povetacicept (10 mg/kg; i.p.; 2 doses (days 1 and 6)) exhibits superior immunosuppressive activity over single-target inhibitors, combination therapy, telitacicept, and anti-CD20 in SRBC-immunized mice, leading to greater suppression of T cell-dependent antibody responses [2]. Povetacicept (17 mg/kg; i.p.; twice weekly; 20 weeks) significantly suppresses lupus disease activity, improves survival, and reduces renal and glandular pathology in the spontaneous NZB/NZW F1 lupus mouse model [2]. Povetacicept (10 mg/kg; i.p.; twice weekly; day 5 to day 88) significantly suppresses renal immune deposition and reduces pathogenic splenic immune cell subsets in the inducible bm12 lupus mouse model [2]. |
| Système d'expression |
Mammalian cells |
| Cible |
TNF- and APOL-related leukocyte expressed ligand 2, APRIL, CD256, Tumor necrosis factor ligand superfamily member 13, TNF-related death ligand 1, TALL-2, TNFSF13, ZTNF2, A proliferation-inducing ligand, TALL2, TRDL-1, BAFF, ZTNF4, BLYS, Tumor necrosis factor ligand superfamily member 13B, Dendritic cell-derived TNF-like molecule, TALL-1, TNF- and APOL-related leukocyte expressed ligand 1, BLyS, B lymphocyte stimulator, TNFSF13B, CD257, TNFSF20, TALL1, B-cell-activating factor |
| Niveau d'endotoxines |
< 10 EU/mg |
| Pureté |
>95% purity as determined by SDS-PAGE. |
| Purification |
Protein A/G purified from cell culture supernatant. |
| Numéro d'accès |
O75888 & Q9Y275 |
| Forme |
Liquid |
| Tampon de stockage |
0.01M PBS pH 7.4 Reférez-vous aux informations spécifiques sur le tampon dans la copie papier du datasheet ou dans le COA spécifique au lot.
|
| Stabilité et stockage |
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt. |
| Noms alternatifs | ALPN-303, povetacicept |
|---|
| Contexte | Povetacicept (ALPN-303), an Fc fusion protein of an engineered TACI domain, is a dual APRIL/BAFF antagonist. Povetacicept modulates B lymphocytes and pathogenic autoantibodies for the study of Lupus and other B cell-related autoimmune diseases.
|
|---|
| Reférences |
1. Stacey Dillon, et al. Povetacicept (ALPN-303; TACI vTD-Fc), an enhanced, potent dual inhibitor of BAFF and APRIL, ameliorates experimental autoimmune myasthenia gravis in C57BL/6N mice. Front. Immunol., 06 June 2025. [HF941056]
2. Evans LS, et al. Povetacicept, an Enhanced Dual APRIL/BAFF Antagonist That Modulates B Lymphocytes and Pathogenic Autoantibodies for the Treatment of Lupus and Other B Cell-Related Autoimmune Diseases. Arthritis Rheumatol. 2023;75(7):1187-1202. [HF941056]
3. Rinaldi E, et al. Povetacicept (ALPN-303; TACI vTD-Fc), an enhanced, potent dual inhibitor of BAFF and APRIL, ameliorates experimental autoimmune myasthenia gravis in C57BL/6N mice. Front Immunol. 2025;16:1533093. Published 2025 Jun 6. [HF941056] |
| Note |
For research use only. Not suitable for clinical or therapeutic use. |
中文
English
한국어
日本語
Español
Français
Русский
